Trump's Next Move: 100 Percent Tariffs on Generic Drugs from 2028
# generic drugs# US tariffs# pharma supply chain
Key Points
- Trump announced 100% tariffs on generic pharmaceuticals starting 2028
- US generics rely heavily on Indian and overseas manufacturing
- Japanese drugmakers and API supply chains face spillover risk
Analysis
Generics fill ninety percent of US prescriptions, mostly made abroad—so a 100% tariff would hit American patients' bills first. For Japanese pharma, threat and opportunity split by footprint: US-based capacity wins, export reliance loses. The 2028 lead time itself hints at negotiating leverage.